Logo image of AEMD

AETHLON MEDICAL INC (AEMD) Stock Fundamental Analysis

NASDAQ:AEMD - Nasdaq - US00808Y4061 - Common Stock - Currency: USD

1.23  -0.11 (-8.21%)

After market: 1.2897 +0.06 (+4.85%)

Fundamental Rating

2

Taking everything into account, AEMD scores 2 out of 10 in our fundamental rating. AEMD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of AEMD is average, but there are quite some concerns on its profitability. AEMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AEMD has reported negative net income.
AEMD had a negative operating cash flow in the past year.
In the past 5 years AEMD always reported negative net income.
AEMD had a negative operating cash flow in each of the past 5 years.
AEMD Yearly Net Income VS EBIT VS OCF VS FCFAEMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

AEMD has a worse Return On Assets (-181.78%) than 91.44% of its industry peers.
The Return On Equity of AEMD (-261.12%) is worse than 78.07% of its industry peers.
Industry RankSector Rank
ROA -181.78%
ROE -261.12%
ROIC N/A
ROA(3y)-131.15%
ROA(5y)-104.21%
ROE(3y)-181.8%
ROE(5y)-137.98%
ROIC(3y)N/A
ROIC(5y)N/A
AEMD Yearly ROA, ROE, ROICAEMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

1.3 Margins

AEMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AEMD Yearly Profit, Operating, Gross MarginsAEMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for AEMD has been increased compared to 1 year ago.
AEMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AEMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AEMD Yearly Shares OutstandingAEMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
AEMD Yearly Total Debt VS Total AssetsAEMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -34.54, we must say that AEMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -34.54, AEMD is doing worse than 91.98% of the companies in the same industry.
There is no outstanding debt for AEMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -34.54
ROIC/WACCN/A
WACCN/A
AEMD Yearly LT Debt VS Equity VS FCFAEMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 3.13 indicates that AEMD has no problem at all paying its short term obligations.
AEMD's Current ratio of 3.13 is in line compared to the rest of the industry. AEMD outperforms 57.75% of its industry peers.
A Quick Ratio of 3.13 indicates that AEMD has no problem at all paying its short term obligations.
The Quick ratio of AEMD (3.13) is better than 65.78% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
AEMD Yearly Current Assets VS Current LiabilitesAEMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 65.99% over the past year.
EPS 1Y (TTM)65.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AEMD will show a very strong growth in Earnings Per Share. The EPS will grow by 39.71% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.11%
EPS Next 2Y39.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AEMD Yearly Revenue VS EstimatesAEMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
AEMD Yearly EPS VS EstimatesAEMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AEMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AEMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AEMD Price Earnings VS Forward Price EarningsAEMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AEMD Per share dataAEMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

AEMD's earnings are expected to grow with 39.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.71%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AEMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AETHLON MEDICAL INC

NASDAQ:AEMD (8/8/2025, 8:18:11 PM)

After market: 1.2897 +0.06 (+4.85%)

1.23

-0.11 (-8.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)06-26 2025-06-26/amc
Earnings (Next)08-12 2025-08-12
Inst Owners21.03%
Inst Owner Change-1.23%
Ins Owners4.5%
Ins Owner Change37.15%
Market Cap3.19M
Analysts80
Price Target3.09 (151.22%)
Short Float %8.93%
Short Ratio0.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-316.69%
Min EPS beat(2)-673.64%
Max EPS beat(2)40.26%
EPS beat(4)1
Avg EPS beat(4)-159.94%
Min EPS beat(4)-673.64%
Max EPS beat(4)40.26%
EPS beat(8)3
Avg EPS beat(8)-76.56%
EPS beat(12)6
Avg EPS beat(12)-50.14%
EPS beat(16)7
Avg EPS beat(16)-44.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-90%
PT rev (3m)-21.94%
EPS NQ rev (1m)23.21%
EPS NQ rev (3m)N/A
EPS NY rev (1m)33.67%
EPS NY rev (3m)-430.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-13.33
EYN/A
EPS(NY)-2.65
Fwd EYN/A
FCF(TTM)-2.95
FCFYN/A
OCF(TTM)-2.95
OCFYN/A
SpS0
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -181.78%
ROE -261.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-131.15%
ROA(5y)-104.21%
ROE(3y)-181.8%
ROE(5y)-137.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -34.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)153.85%
Cap/Depr(5y)180.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.48%
EPS Next Y80.11%
EPS Next 2Y39.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.52%
OCF growth 3YN/A
OCF growth 5YN/A